Case Report: Inflammatory Sternoclavicular Joint Arthritis Induced by an Immune Checkpoint Inhibitor with Remarkable Responsiveness to Infliximab

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 May 27

PMID 38799449

Authors

Shion Kachi

Shuji Sumitomo

Hideki Oka

Akito Hata

Koichiro Ohmura

Affiliations

Soon will be listed here.

Abstract

This report describes the case of a 48-year-old woman who presented with sternoclavicular joint arthritis after administration of an immune checkpoint inhibitor (ICI), durvalumab, for small cell lung carcinoma. The onset of arthritis transpired 18 months after the commencement of the ICI therapeutic regimen and demonstrated resilience to glucocorticoid treatment. After excluding infectious aetiologies and metastatic involvement, the patient was diagnosed with ICI-induced arthritis (ICI-IA). Considering the articular implications akin to the SAPHO syndrome, the patient was treated with infliximab, resulting in complete resolution. This finding implies that biological DMARDs can serve as effective interventions for ICI-induced sternoclavicular joint arthritis. Given the heterogeneous nature of its pathogenesis, the selection of therapeutic agents may require customization based on the distinct clinical presentation of each individual case.

Citing Articles

Zhang M, Fu Y, Song Y, Gao X, Wang J, Zhang B Front Pharmacol. 2024; 15:1454015.

PMID: 39494351 PMC: 11527638. DOI: 10.3389/fphar.2024.1454015.

References

Figueiredo A, Oliveira A, Caetano A, Moraes-Fontes M . SAPHO: has the time come for tailored therapy?. Clin Rheumatol. 2019; 39(1):177-187. DOI: 10.1007/s10067-019-04675-2. View

Feist J, Murray A, Skapenko A, Schulze-Koops H . A Rare Side Effect of Checkpoint Inhibitor Therapy-Nivolumab-Induced Axial Polyarthritis of the Facet and Costovertebral Joints. Arthritis Rheumatol. 2019; 71(11):1823. DOI: 10.1002/art.41036. View

Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa M, Belsue V . Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019; 569(7756):428-432. DOI: 10.1038/s41586-019-1162-y. View

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C . Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2017; 77(3):393-398. DOI: 10.1136/annrheumdis-2017-212257. View

Brahmer J, Lacchetti C, Schneider B, Atkins M, Brassil K, Caterino J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17):1714-1768. PMC: 6481621. DOI: 10.1200/JCO.2017.77.6385. View

Walsh M, Ali L, Lenehan P, Kureshi C, Kureshi R, Dougan M . Blockade of innate inflammatory cytokines TNF, IL-1, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. Immunother Adv. 2023; 3(1):ltad011. PMC: 10349916. DOI: 10.1093/immadv/ltad011. View

Das S, Johnson D . Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7(1):306. PMC: 6858629. DOI: 10.1186/s40425-019-0805-8. View

Albayda J, Bingham 3rd C, Shah A, Kelly R, Cappelli L . Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford). 2018; 57(4):760-762. PMC: 6251606. DOI: 10.1093/rheumatology/kex470. View

Kostine M, Finckh A, Bingham C, Visser K, Leipe J, Schulze-Koops H . EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2020; 80(1):36-48. PMC: 7788064. DOI: 10.1136/annrheumdis-2020-217139. View

10.

Cappelli L, Thomas M, Bingham 3rd C, Shah A, Darrah E . Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis. Immunol Rev. 2020; 294(1):106-123. PMC: 7047521. DOI: 10.1111/imr.12832. View

11.

Kostine M, Truchetet M, Schaeverbeke T . Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (Oxford). 2019; 58(Suppl 7):vii68-vii74. PMC: 6900916. DOI: 10.1093/rheumatology/kez295. View

12.

de Malet A, Antoni G, Collins M, Soularue E, Marthey L, Vaysse T . Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer. 2018; 106:106-114. DOI: 10.1016/j.ejca.2018.10.006. View

13.

Cappelli L, Kamal O, Jones M, Bingham 3rd C, Shah A . Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2023; 63(6):1518-1522. PMC: 11147537. DOI: 10.1093/rheumatology/kead438. View

14.

Depasquale R, Kumar N, Lalam R, Tins B, Tyrrell P, Singh J . SAPHO: What radiologists should know. Clin Radiol. 2011; 67(3):195-206. DOI: 10.1016/j.crad.2011.08.014. View

15.

Bass A, Abdel-Wahab N, Reid P, Sparks J, Calabrese C, Jannat-Khah D . Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023; 82(7):920-926. PMC: 10330686. DOI: 10.1136/ard-2023-223885. View

16.

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T . TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017; 8(1):2256. PMC: 5741628. DOI: 10.1038/s41467-017-02358-7. View

17.

Robinson C, Jenkins P, Markham P, Beggs I . Disorders of the sternoclavicular joint. J Bone Joint Surg Br. 2008; 90(6):685-96. DOI: 10.1302/0301-620X.90B6.20391. View

18.

Braaten T, Brahmer J, Forde P, Le D, Lipson E, Naidoo J . Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2019; 79(3):332-338. PMC: 7031780. DOI: 10.1136/annrheumdis-2019-216109. View

19.

Cappelli L, Gutierrez A, Bingham 3rd C, Shah A . Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken). 2016; 69(11):1751-1763. PMC: 5478477. DOI: 10.1002/acr.23177. View